PROBLEMS IN PHARMACOTHERAPY OF RESISTANT ARTERIAL HYPERTENSION
https://doi.org/10.15829/1560-4071-2013-6-76-79
Abstract
The paper focuses on the problems in the treatment of patients with resistant arterial hypertension. The relevant recommendations from the European guidelines are presented. Angiotensin receptor antagonists are considered as a group of antihypertensive agents with additional benefits and good tolerability. The evidence on antihypertensive combination therapy is also presented.
About the Authors
N. V. Teplova
Hospital Therapy Department No. 1, Therapy Faculty, N.I. Pirogov Russian National Medical Research University, Moscow, Russia
Russian Federation
Russian Federation
E. O. Taratukhin
Hospital Therapy Department No. 1, Therapy Faculty, N.I. Pirogov Russian National Medical Research University, Moscow, Russia
Russian Federation
Russian Federation
References
1. Fagard R. H. Resistant hypertension. Heart 2012; 98:254–61.
2. Mancia G., Fagard R., Narkiewicz K. et al. 2013 ESHESC Guidelines for the management of arterial hypertension. European Heart Journal, 2013; doi:10.1093/eurheart/eht151 — с.46.
3. Poteshkina N. G. Salt consumption. Cardiovascular system as a target organ. Part III. Russ J Cardiol 2012; 6 (98): 84–90. Потешкина Н. Г. Потребление соли. Сердечно-сосудистая система как орган-мишень. Ч.3. Российский кардиологический журнал, 2012;6 (98): 84–90.
4. Persell S. D. Prevalence of resistant hypertension in the United States, 2003–2008. Hypertension 2011; 57:1076–80.
5. Bobrie G., Frank M., Azizi M. et al. Sequential nephron blockade vs. sequential reninangiotensin system blockade in resistant hypertension: a prospective, randomized, open blinded endpoint study. J Hypertens 2012; 30:1656–64.
6. Laurent S., Schlaich M., Esler M. New drugs procedures and devices for hypertension. Lancet 2012; 380:591–600.
7. Mancia G., Fagard R., Narkiewicz K. et al. 2013 ESHESC Guidelines for the management of arterial hypertension. European Heart Journal, 2013; doi:10.1093/eurheart/eht151 — c.30
8. Roberie D. R., Elliott W. J. What is the prevalence of resistant hypertension in the United States? Curr Opin Cardiol. 2012 Jul; 27 (4):386–91.
9. Ogihara T., Saruta T., Rakugi H. et al. Target blood pressure for treatment of isolated systolic hypertension in the elderly: Valsartan in Elderly Isolated Systolic Hypertension Study. Hypertension 2010; 56:196–202.
10. Reboldi G., Gentile G., Angeli F. et al. Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73,913 patients. J Hypertens 2011; 29:1253–69.
11. Mavromoustakos T., Agelis G., Durdagi S. AT1 antagonists: a patent review (2008–2012). Expert Opin Ther Pat. 2013 Nov; 23 (11):1483–94.
12. Volpe M., Tocci G. Olmesartan in the Treatment of Hypertension in Elderly Patients: a Review of the Primary Evidence. Drugs Aging, 2013 — October 30.
13. Miura S. I., Saku K. Recent progress in the treatment of cardiovascular disease using olmesartan. Clin Exp Hypertens, 2013; October 28.
14. Saseen J. J., Ghushchyan V., Kaila S. et al. Maintaining Goal Blood Pressures After Switching From Olmesartan to Other Angiotensin Receptor Blockers. J Clin Hypertens (Greenwich), 2013 Sep 19. doi: 10.1111/jch.12197.
15. Bramlage P., Zemmrich C., Ketelhut R., et al. Safety, tolerability, and efficacy of a fixeddose combination of olmesartan 40 mg and hydrochlorothiazide 12.5/25 mg in daily practice. Vasc Health Risk Manag. 2013; 9: 475–83.
16. Imai E., Haneda M., Yamasaki T. et al. Effects of dual blockade of the renin-angiotensin system on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy and hypertension in the ORIENT: a post-hoc analysis (ORIENT-Hypertension). Hypertens Res. 2013 Sep 12. doi: 10.1038/hr.2013.86.
17. Pelisch N., Hosomi N., Mori H. et al. RAS inhibition attenuates cognitive impairment by reducing blood- brain barrier permeability in hypertensive subjects. Curr Hypertens Rev. 2013 May; 9 (2):93–8.
18. Sugimoto D. H., Chrysant S. G., Melino M. et al. The TRINITY Study: distribution of systolic blood pressure reductions. Integr Blood Press Control. 2013 Jul 12; 6:89–99.
19. Roth E. M., Oparil S., Melino M. et al. Olmesartan/amlodipine/hydrochlorothiazide in obese participants with hypertension: a TRINITY subanalysis. J Clin Hypertens (Greenwich).
20. Aug; 15 (8):584–92.
21. Kario K., Saito I., Kushiro T. et al. Effect of the angiotensin II receptor antagonist olmesartan on morning home blood pressure in hypertension: HONEST Study at 16 weeks. J Hum Hypertens. 2013 Jul 18. doi: 10.1038/jhh.2013.68.
Review
For citations:
Teplova N.V., Taratukhin E.O. PROBLEMS IN PHARMACOTHERAPY OF RESISTANT ARTERIAL HYPERTENSION. Russian Journal of Cardiology. 2013;(6):76-79. (In Russ.) https://doi.org/10.15829/1560-4071-2013-6-76-79
Views:
562
Email this article 